Early treatment burden predicts recurrence or progression after bronchoscopic intervention for infection- or injury-related benign airway stenosis: A two-center longitudinal cohort study
Therapeutic Advances in Respiratory Disease · 2026
DOI: 10.1177/17534666261483782 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Therapeutic Advances in Respiratory Disease, 2026. Verfasst von Jiaping Liu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China. Hauptthemen laut MEDLINE: Bronchoscopy, Airway Obstruction, Bronchial Diseases. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Patients with infection- or injury-related benign airway stenosis often require repeated bronchoscopic interventions, but evidence is limited on how early treatment patterns can guide follow-up and risk reassessment.
Objectives
To derive phase-adapted surveillance windows after bronchoscopic intervention and determine whether the 24-week treatment trajectory identifies patients at increased risk of subsequent recurrence or progression.
Design
Two-center retrospective longitudinal cohort study.
Methods
Patients treated between January 2019 and December 2024 were included if they had infection- or injury-related benign airway stenosis and did not receive stent or T-tube placement during follow-up. Adjacent bronchoscopic records separated by ≤1 week were merged into one treatment episode. Valid intervals were defined as adjacent records separated by >1 week with assessable recurrence/progression status. Risk strata were constructed using treatment episodes within 24 weeks and window-end airway control: low risk, 1–3 episodes with adequate control; intermediate risk, 4–5 episodes or 1–3 episodes with inadequate control; and high risk, ≥6 episodes. A 24-week landmark analysis evaluated subsequent composite events.
Results
Overall, 213 patients contributed 879 valid intervals. Data-informed surveillance windows were approximately 1 week in the early phase, 2–3 weeks in the mid and consolidation phases, and 4–5 weeks in the maintenance phase. Among 93 patients included in landmark analysis, post-landmark composite event proportions were 31.3%, 60.9%, and 80.6% in the low-, intermediate-, and high-risk groups, respectively (log-rank P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.
- Beijing University of Chinese Medicine, Beijing, China.
- Emergency General Hospital, Beijing, China.
ORCID-Profile: Hongwu Wang
Zitieren
APA
Liu, J., Wang, Z., Lin, Y., Zou, H., Pan, S., Chen, S., Gao, H., Zhang, N., & Wang, H. (2026). Early treatment burden predicts recurrence or progression after bronchoscopic intervention for infection- or injury-related benign airway stenosis: A two-center longitudinal cohort study. Therapeutic Advances in Respiratory Disease. https://doi.org/10.1177/17534666261483782
Vancouver
Liu J, Wang Z, Lin Y, Zou H, Pan S, Chen S, et al. Early treatment burden predicts recurrence or progression after bronchoscopic intervention for infection- or injury-related benign airway stenosis: A two-center longitudinal cohort study. Therapeutic Advances in Respiratory Disease. 2026. doi:10.1177/17534666261483782
BibTeX
@article{Liu2026,
author = {Liu, Jiaping and Wang, Zhina and Lin, Ying and Zou, Heng and Pan, Shujuan and Chen, Shuiping and Gao, Hong and Zhang, Nan and Wang, Hongwu},
title = {Early treatment burden predicts recurrence or progression after bronchoscopic intervention for infection- or injury-related benign airway stenosis: A two-center longitudinal cohort study},
journal = {Therapeutic Advances in Respiratory Disease},
year = {2026},
doi = {10.1177/17534666261483782}
}
EUVIMED